Results 201 to 210 of about 279,218 (267)

Strategies to inhibit steroid cytochrome P450 enzymes to benefit human health: development of steroid ligands for P450s 17A1, 19A1, and 8B1 to treat cancer and obesity. [PDF]

RSC Med Chem
Ho TM, Yoshimoto FK.
europepmc   +1 more source

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

Clinical Pharmacology &Therapeutics, EarlyView.
Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis.
Zubida M. Al‐Majdoub, Martyn Howard, Brahim Achour, Jill Barber, Naved Alizai, Amin Rostami‐Hodjegan   +5 more
wiley   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source

Molecular Mechanisms Underlying the Anti-Cancer Effects of Tangeretin, a Phytochemical from Citrus Extracts. [PDF]

Biomol Ther (Seoul)
Ahn SH, Choi KC.
europepmc   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Multilocus sequence typing and genomic characterization of the novel Streptomyces strain SCPE-10, that resists 2,4-D toxicity and has bioremediation potential. [PDF]

Braz J Microbiol
Nhampossa NA, de Almeida Araújo JVC, da Silva VAS, Amaral JRV, da Conceição CS, Gonçalves CAX, Squizani ED, da Silva S, Vidal MS, Chen Y, Macrae A, do Nascimento RP.   +11 more
europepmc   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source

Increased mutation rates and diversity are dominant features of <i>Geobacter</i> multiheme cytochromes. [PDF]

mBio
Starwalt-Lee R, Gralnick JA, Bond DR.
europepmc   +1 more source